Efficient delivery of tumor-associated antigens to professional antigen-presenting cells is important for inducing a response in patients receiving cancer immunotherapy. Interferon-gamma (IFN-γ) is used by the immune system to combat viral and fungal infections by restricting cell proliferation and, in some cases, inducing apoptosis. Using IFN-γ to activate target tumor cells prior to antigen loading of dendritic cells (DCs) may enhance the beneficial qualities of whole-cell tumor vaccines. The incubation of melanoma cell cultures with IFN-γ resulted in an increase in the expression of major histocompatibility complex molecules and ICAM-1 but generally decreased the expression of melanoma-associated tumor antigens. Additionally, important immune-stimulating molecules (heat-shock proteins, high-mobility group box-1 protein, and calreticulin) were also present but differentially regulated by IFN-γ. Loading of DCs with IFN-γ-treated tumor cells resulted in a small but significant increase in the expression of CD83-positive DCs, indicating the initiation of DC maturation (p=0.019). IFN-γ treatment of melanoma cell lines prior to antigen loading of DCs may aid in antigen processing and presentation.
Get full access to this article
View all access options for this article.
References
1.
LinosE, SwetterSM, CockburnMGet al.Increasing burden of melanoma in the United States. J Invest Dermatol, 2009; 129:1666.
MortariniR, BelliF, ParmianiGet al.Cytokine-mediated modulation of HLA-class II, ICAM-1, LFA-3 and tumor-associated antigen profile of melanoma cells. Comparison with anti-proliferative activity by rIL1-beta, rTNF-alpha, rIFN-gamma, rIL4 and their combinations. Int J Cancer, 1990; 45:334.
4.
MeyskensFLJr., KopeckyKJ, TaylorCWet al.Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: A Southwest Oncology Group study. J Natl Cancer Inst, 1995; 87:1710.
KirkinAF, thor StratenP, ZeuthenJ. Differential modulation by interferon gamma of the sensitivity of human melanoma cells to cytolytic T cell clones that recognize differentiation or progression antigens. Cancer Immunol Immunother, 1996; 42:203.
7.
HofbauerGF, GeertsenR, LaineEet al.Impact of interferons on the expression of melanoma-associated antigens in melanoma short-term cell cultures. Melanoma Res, 2001; 11:213.
ObeidM, TesniereA, GhiringhelliFet al.Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med, 2007; 13:54.
10.
TesniereA, ApetohL, GhiringhelliFet al.Immunogenic cancer cell death: A key-lock paradigm. Curr Opin Immunol, 2008; 20:504.
11.
TodrykS, MelcherAA, HardwickNet al.Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. J Immunol, 1999; 163:1398.
12.
SuzueK, ZhouX, EisenHNet al.Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway. Proc Natl Acad Sci U S A, 1997; 94:13146.
13.
DillmanRO, SelvanSR, SchiltzPMet al.Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: Final report. Cancer Biother Radiopharm, 2009; 24:311.
14.
ChoiD, PerrinM, HoffmannSet al.Dendritic cell-based vaccines in the setting of peripheral blood stem cell transplantation: CD34+ cell-depleted mobilized peripheral blood can serve as a source of potent dendritic cells. Clin Cancer Res, 1998; 4:2709.
15.
LuftT, PangKC, ThomasEet al.A serum-free culture model for studying the differentiation of human dendritic cells from adult CD34+ progenitor cells. Exp Hematol, 1998; 26:489.
16.
DillmanRO, NayakSK, BeutelL. Establishing in vitro cultures of autologous tumor cells for use in active specific immunotherapy. J Immunother Emphasis Tumor Immunol, 1993; 14:65.
17.
DillmanRO, BeutelLD, CornforthANet al.Short-term tumor cell lines from renal cell carcinoma for use as autologous tumor cell vaccines in the treatment of kidney cancer. Cancer Biother Radiopharm, 2000; 15:161.
18.
SelvanSR, CarbonellDJ, FowlerAWet al.Establishment of stable cell lines for personalized melanoma cell vaccine. Melanoma Res, 2010; 20:280.
19.
SelvanSR, DillmanRO, FowlerAWet al.Monitoring response to treatment in melanoma patients: Potential of a serum glycomic marker. Int J Cancer, 2007; 122:1374.
20.
CornforthAN, FowlerAW, CarbonellDJet al.Resistance to the proapoptotic effects of interferon-gamma on melanoma cells used in patient-specific dendritic cell immunotherapy is associated with improved overall survival. Cancer Immunol Immunother, 2010; 60:123.
21.
HamaiA, MeslinF, BenlalamHet al.ICAM-1 has a critical role in the regulation of metastatic melanoma tumor susceptibility to CTL lysis by interfering with PI3K/AKT pathway. Cancer Res, 2008; 68:9854.
22.
TyringSK, KlimpelG, BryskMet al.Eradication of cultured human melanoma cells by immune interferon and leukocytes. J Natl Cancer Inst, 1984; 73:1067.
23.
DolanBP, GibbsKDJr., Ostrand-RosenbergS. Dendritic cells cross-dressed with peptide MHC class I complexes prime CD8+ T cells. J Immunol, 2006; 177:6018.
24.
DolanBP, GibbsKDJr., Ostrand-RosenbergS. Tumor-specific CD4+ T cells are activated by “cross-dressed” dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines. J Immunol, 2006; 176:1447.
25.
AdemaGJ, de VriesIJ, PuntCJet al.Migration of dendritic cell based cancer vaccines: In vivo veritas?Curr Opin Immunol, 2005; 17:170.
26.
DillmanRO, DePriestC, DeLeonCet al.Patient-specific vaccines derived from autologous tumor cell lines as active specific immunotherapy: Results of exploratory phase I/II trials in patients with metastatic melanoma. Cancer Biother Radiopharm, 2007; 22:309.
27.
O'RourkeMG, JohnsonMK, LanaganCMet al.Dendritic cell immunotherapy for stage IV melanoma. Melanoma Res, 2007; 17:316.
28.
DillmanRO, SelvanSR, SchiltzPM. Patient-specific dendritic-cell vaccines for metastatic melanoma. N Engl J Med, 2006; 355:1179.
29.
LotemM, MachlenkinA, HamburgerTet al.Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells. Clin Cancer Res, 2009; 15:4968.
30.
IpWK, LauYL. Distinct maturation of, but not migration between, human monocyte-derived dendritic cells upon ingestion of apoptotic cells of early or late phases. J Immunol, 2004; 173:189.
31.
InzkirweliN, GuckelB, SohnCet al.Antigen loading of dendritic cells with apoptotic tumor cell-preparations is superior to that using necrotic cells or tumor lysates. Anticancer Res, 2007; 27:2121.
32.
SporriR, Reis e SousaC. Newly activated T cells promote maturation of bystander dendritic cells but not IL-12 production. J Immunol, 2003; 171:6406.
33.
YamazakiS, IyodaT, TarbellKet al.Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J Exp Med, 2003; 198:235.
34.
BanerjeeDK, DhodapkarMV, MatayevaEet al.Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood, 2006; 108:2655.
35.
FujiiS, LiuK, SmithCet al.The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J Exp Med, 2004; 199:1607.
36.
CornforthAN, LeeGJ, FowlerAWet al.Increases in serum TARC/CCL17 levels are associated with progression-free survival in advanced melanoma patients in response to dendritic cell-based immunotherapy. J Clin Immunol, 2009; 29:657.
37.
LespagnardL, MettensP, De SmedtTet al.The immune response induced in vivo by dendritic cells is dependent on B7-1 or B7-2, but the inhibition of both signals does not lead to tolerance. Int Immunol, 1998; 10:295–304.
38.
PrazmaCM, TedderTF. Dendritic cell CD83: a therapeutic target or innocent bystander?Immunol Lett, 2008; 115:1.
39.
VerdijkP, AarntzenEH, LesterhuisWJet al.Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res, 2009; 15:2531.
